Novel and Emerging Mechanisms of Action in Myasthenia Gravis

Nicholas Silvestri, MD, FAAN, discusses the level of awareness of myasthenia gravis (MG) and generalized MG among primary care physicians and the public, and the type of harm patients might sustain if they do not receive timely treatment.

Nicholas Silvestri, MD, FAAN, reviews the standard of care and initial treatments patients with myasthenia gravis (MG) receive, as well as several new treatment options that have recently become available for MG (eculizumab, efgartigimod alfa-fcab, ravulizumab-cwvz).

Nicholas Silvestri, MD, FAAN, discusses neonatal Fc receptor and how it contributes to the pathophysiology of myasthenia gravis, as well as the study design, efficacy, safety, and quality-of-life data with efgartigimod phase 3 ADAPT study.

Nicholas Silvestri, MD, FAAN, shares clinical results with eculizumab and ravulizumab, as well as which patients should use biologics and when during the treatment journey.

Nicholas Silvestri, MD, FAAN, reviews investigational agents and ongoing studies in the pipeline, as well as advice for earlier engagement and evaluation of patients for myasthenia gravis to hasten treatment.